Global Peptide Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431609
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Bachem Holding AG
  • GlaxoSmithKline plc
  • Lonza, Inc.
  • Novartis AG
  • Peptisyntha
  • MORE
Peptide Therapeutics Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2017 - 2025, the peptide therapeutics market was valued at USD 23,293.0 Mn in 2017, and is expected to reach USD 90,174.7 Mn by 2025, expanding at a CAGR of 9.8% from 2017 to 2025.

Market Insights

Peptide therapeutics were observed as one of the most attractive and preferred options in recombinant medicine. The advantages such as low toxicity, high specificity, and much lower molecular weight makes it easy to set up dosage plans for patients. However, therapeutic peptides were introduced into the market couple of decades back, its market share and growth has significantly increased in past five or six years. The key factors assisting the global peptide therapeutics market are rising healthcare expenditure along with increasing importance of healthcare sector in developing countries. The main disease indications that are driving the demand for peptide therapeutics are cancer, metabolic disorders, and central nervous systems. Application of peptide therapeutics in oncology treatment is increasing mainly due to high mortality rate and moderately due to broader focus on emerging alternatives therapies to chemotherapy. The key application of peptide therapeutics is into oncology mainly used for treating prostrate, pancreatic, ovarian, and breast cancer. During preclinical stages efficacy testing of peptides in oncology treatment especially focusing on its property of being antagonists or agonists to specific receptors is tested.

In 2015, cancer segment accounted of the major market share due to rising prevalence of cancers coupled with high disease diagnosis rate, rising public awareness associated with the peptide therapeutics and developing overall healthcare infrastructure and supportive government policies. In 2015, solid phase peptide synthesis accounted for the largest market share due to introduction of novel products equipped with SPPS especially focusing on oral route of drug delivery. Some of the examples such as initially Unigene and then Enteris Biopharma developed a technology named Peptelligence which is based on an enteric-coated tablet, whose core formulation comprises, along with peptide, an organic acid enzyme inhibitor and permeation enhancer which is claimed to help penetrate the mucus layer. North America was observed as the largest market in peptide therapeutics industry due to factors such as high awareness associated with therapeutic treatment developments in public, high acceptance for novel products and technologies from patients and medical practitioners, and high healthcare costs.

According to market experts, in the near future peptide therapeutics is expected to be a huge breakthrough for both patients and drug manufacturing companies. In manufacturing and development of non-invasive delivery technologies, cost optimization is expected to generate significant revenue growth and better treatment outcomes for the patients.

Key Market Movements:
  • Rising prevalence of cancer and metabolic disorders across the world
  • Incessant growth in research and development coupled with technological advances in field of therapeutic treatment
  • Along with expected drug approvals in peptide therapeutics market the upcoming patent cliff for drugs available in existing market is anticipated to create opportunity for generic peptides
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Bachem Holding AG
  • GlaxoSmithKline plc
  • Lonza, Inc.
  • Novartis AG
  • Peptisyntha
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Peptide Therapeutics Market, by Technology Type, 2015 - 2025 (Value %)
2.2 Global Peptide Therapeutics Market, by Delivery Route Type, 2015 - 2025 (Value %)
2.3 Global Peptide Therapeutics Market, by Application Type, 2015 (USD Mn)
2.4 Global Peptide Therapeutics Market, by Geography, 2015 (Value %)

Chapter 3 Global Peptide Therapeutics Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Rising prevalence of cancer is boosting the need for research and development in Peptide Therapeutics
3.2.2 Incessant growth in research and development coupled with technological advances in field of therapeutic treatment
3.3 Market Restraints
3.3.1 Complex manufacturing techniques are increasing intricacy for API manufacturers in peptide therapeutics industry
3.4 Market Opportunities
3.4.1 Along with expected drug approvals in peptide therapeutics market the upcoming patent cliff for drugs available in existing market
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Peptide Therapeutics, by Key Players

Chapter 4 Global Peptide Therapeutics Market Analysis, By Technology Type
4.1 Overview
4.2 Solid Phase Peptide Synthesis (SPPS)
4.3 Liquid Phase Peptide Synthesis (LPPS)
4.4 Hybrid Phase Peptide Synthesis (HPPS)

Chapter 5 Global Peptide Therapeutics Market Analysis, By Delivery Route
5.1 Overview
5.2 Oral Route
5.3 Parenteral Route
5.4 Pulmonary Route
5.5 Mucosal Route
5.6 Other Routes (Intradermal & Nasal)

Chapter 6 Global Peptide Therapeutics Market Analysis, By Applications
6.1 Overview
6.2 Cancer
6.3 Cardiovascular Diseases
6.4 Metabolic Diseases
6.5 Central Nervous System
6.6 Infectious Diseases
6.7 Gastrointestinal Diseases
6.8 Renal Disorders
6.9 Others(Pain Management, Dermatological Disorders, and Hematological Disorders)

Chapter 7 Global Peptide Therapeutics Market, By Geography
7.1 Preface
7.2 North America (U.S. & Canada)
7.3 Europe (U.K, Germany, and Rest of the Europe)
7.4 Asia-Pacific (China, Japan, and Rest of Asia-Pacific)
7.5 Latin America (Brazil, Mexico, and Rest of LATAM)
7.6 Middle East and Africa

Chapter 8 Company Profiles
8.1 Amgen Inc.
8.2 Amylin Pharmaceuticals LLC (Bristol- Myers Squibb)
8.3 AstraZeneca plc
8.4 Bachem Holding AG
8.5 Eli Lilly and Company
8.6 GlaxoSmithKline plc
8.7 Ipsen
8.8 Lonza, Inc.
8.9 Merck & Co.
8.10 Novartis AG
8.11 Novo- Nordisk A/S
8.12 Peptisyntha
8.13 PolyPeptide Group
8.14 Pfizer, Inc.
8.15 F. Hoffman-La Roche AG
8.16 Sanofi S.A.
8.17 Takeda Pharmaceutical Company Limited
8.18 Teva Pharmaceuticals

List of Figures
Fig. 1 Peptide Therapeutics Market: Research Methodology
Fig. 2 Global Peptide Therapeutics Market, by Technology Type, 2015 v/s 2024 (Value %)
Fig. 3 Global Peptide Therapeutics Market, by Delivery Route Type, 2015 v/s 2024 (Value %)
Fig. 4 Global Peptide Therapeutics Market, by Application Type, 2015 (USD Mn)
Fig. 5 Global Peptide Therapeutics Market, by Geography, 2015 (Value %)
Fig. 6 Attractive Investment Proposition, by Geography, 2015
Fig. 7 Global Solid Phase Peptide Synthesis (SPPS) Technology Market in Peptide Therapeutics, 2015 - 2025 (USD Mn)
Fig. 8 Global Liquid Phase Peptide Synthesis (LPPS) Market in Peptide Therapeutics, 2015 - 2025 (USD Mn)
Fig. 9 Global Hybrid Phase Peptide Synthesis (HPPS) Market in Peptide Therapeutics, 2015 - 2025 (USD Mn)
Fig. 10 Global Oral Route Drug Delivery Market in Peptide Therapeutics, 2015 - 2025 (USD Mn)
Fig. 11 Global Parenteral Route Drug Delivery Market in Peptide Therapeutics, 2015 - 2025 (USD Mn)
Fig. 12 Global Pulmonary Route Drug Delivery Market in Peptide Therapeutics, 2015 - 2025 (USD Mn)
Fig. 13 Global Mucosal Route Drug Delivery Market in Peptide Therapeutics, 2015 - 2025 (USD Mn)
Fig. 14 Global Other Routes Drug Delivery Market in Peptide Therapeutics, 2015 - 2025 (USD Mn)
Fig. 15 Global Peptide Therapeutics Application Market in Cancer Treatment, 2015 - 2025 (USD Mn)
Fig. 16 Global Peptide Therapeutics Application Market in Cardiovascular Diseases Treatment, 2015 - 2025 (USD Mn)
Fig. 17 Global Peptide Therapeutics Application Market in Metabolic Diseases Treatment, 2015 - 2025 (USD Mn)
Fig. 18 Peptide Therapeutics Application Market in Central Nervous System Disorder Treatment, 2015 - 2025 (USD Mn)
Fig. 19 Peptide Therapeutics Application Market in Respiratory Diseases Treatment, 2015 - 2025 (USD Mn)
Fig. 20 Peptide Therapeutics Application Market in Infectious Diseases Treatment, 2015 - 2025 (USD Mn)
Fig. 21 Peptide Therapeutics Application Market in Gastrointestinal Diseases Treatment, 2015 - 2025 (USD Mn)
Fig. 22 Peptide Therapeutics Application Market in Renal Disorders Treatment, 2015 - 2025 (USD Mn)
Fig. 23 Peptide Therapeutics Application Market in Other Disorders Treatment, 2015 - 2025 (USD Mn)
Fig. 24 North America Peptide Therapeutics Market, 2015 - 2025 (USD Mn)
Fig. 25 Europe Peptide Therapeutics Market, 2015 - 2025 (USD Mn)
Fig. 26 Asia-Pacific Peptide Therapeutics Market, 2015 - 2025 (USD Mn)
Fig. 27 Latin America Peptide Therapeutics Market, 2015 - 2025 (USD Mn)
Fig. 28 Middle East and Africa Peptide Therapeutics Market, 2015 - 2025 (USD Mn)

List of Tables
Table 1 Market Competition Assessment: Peptide Therapeutics, by Key Players
Table 2 Global Peptide Therapeutics Market, by Technology Type, 2014-2023 (USD Mn)
Table 3 Global Peptide Therapeutics Market, by Delivery Route, 2015 - 2025 (USD Mn)
Table 4 Global Peptide Therapeutics Market, by Applications, 2015 - 2025 (USD Mn)
Table 5 Global Peptide Therapeutics Market, by Geography, 2015 - 2025 (USD Mn)
Table 6 Amgen Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 7 Amylin Pharmaceuticals LLC (Bristol- Myers Squibb): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 8 AstraZeneca plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 9 Bachem Holding AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 10 Eli Lilly and Company: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 11 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 12 Ipsen: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 13 Lonza, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 14 Merck & Co.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 15 Novartis AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 16 Novo- Nordisk A/S: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 17 Peptisyntha: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 18 PolyPeptide Group: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 19 Pfizer, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 20 F. Hoffman-La Roche AG: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 21 Sanofi S.A.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 22 Takeda Pharmaceutical Company Limited: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Table 23 Teva Pharmaceuticals: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Amgen Inc.
  • Amylin Pharmaceuticals LLC (Bristol- Myers Squibb)
  • AstraZeneca plc
  • Bachem Holding AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Ipsen
  • Lonza, Inc.
  • Merck & Co.
  • Novartis AG
  • Novo- Nordisk A/S
  • Peptisyntha
  • PolyPep
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll